Table of Contents
Executive Summary — 7
SWOT
Analysis — 8
Indonesia Pharmaceutical And Healthcare
Industry SWOT — 8
Indonesia Political
SWOT — 9
Indonesia Economic SWOT — 10
Indonesia Business Environment SWOT — 10
Pharmaceutical
Business Environment Ranking — 11
Table: Asia Pacific
Pharmaceutical Business Environment Ratings (BERs) for
Q409 — 11
Limits of Potential
Returns — 12
Risks to Realisation of
Returns — 12
Market Summary –
Indonesia — 14
Regulatory Regime — 16
Intellectual Property Issues — 16
Generic Drug
Legislation — 18
Labelling
Requirements — 18
Counterfeit and Substandard
Drugs — 19
Free Trade Agreements — 20
Pricing Regime — 21
Price Cuts — 22
Reimbursement Regime — 23
Industry Trends and
Developments — 24
Epidemiology — 24
Recent Public Health Developments — 25
Table: UN
Millennium Development Goals — 26
Avian and Swine
Flu — 27
International Avian Flu
Partnerships — 28
Healthcare
System — 29
Healthcare System
Reform — 30
International Healthcare
Collaborations — 31
Pharmaceutical Retail
Sector — 32
Research and
Development — 32
Herbal Medicines — 33
Medical Devices — 34
Industry Forecast
Scenario — 36
Overall Market
Forecast — 36
Table: Indonesia – Drug Expenditure
Indicators, Historical Data and Forecasts — 37
Key Growth
Factors – Industry — 38
Table: Indonesia –
Health Expenditure Indicators, Historical Data and
Forecasts — 39
Key Growth Factors –
Macroeconomic — 40
Table: Indonesia - Economic Activity,
2006-2013 — 42
Prescription Market
Forecasts — 43
Table: Indonesia – Prescription
Market Indicators, Historical Data and Forecasts (US$mn unless otherwise
stated) — 44
Patented Market
Forecast — 45
Table: Indonesia – Patented Drug
Market Indicators, Historical Data and Forecasts — 46
Generics Market Forecast — 47
Table: Indonesia –
Generic Drug Market, Historical Data and Forecasts — 48
OTC Market Forecast — 49
Table: Indonesia – OTC Drug
Market, Historical Data and Forecasts (US$mn unless otherwise
stated) — 50
Medical Devices Market
Forecast — 51
Table: Indonesia – Medical Device
Market Indicators, Historical Data and Forecasts — 52
Pharmaceutical Trade Forecast — 53
Table: Indonesia
– Pharmaceutical Trade Indicators, Historical Data and Forecasts
(US$mn) — 55
Other Healthcare Data and
Forecasts — 56
Table: Indonesia – Other Health
Indicators, Historical Data and Forecasts — 56
Key Risks
to BMI’s Forecast Scenario — 57
Competitive
Landscape — 58
Pharmaceutical
Sector — 58
Domestic Industry — 59
Foreign Industry — 60
Recent Pharmaceutical Sector
Developments — 60
Company
Profiles — 63
Leading Foreign
Manufacturers — 63
Sanofi-Aventis — 63
Pfizer — 65
Novartis — 66
GlaxoSmithKline (GSK) — 68
Merck &
Co — 69
Bayer — 70
Indigenous
Manufacturers — 72
PT Kalbe Farma — 72
PT Bio Farma — 76
Kimia Pharma — 78
PT
Sido Muncul — 81
Combiphar PT — 82
Country Snapshot: Indonesia Demographic Data — 84
Section
1: Population — 84
Table: Demographic Indicators,
2005-2030 — 84
Table: Rural/Urban Breakdown,
2005-2030 — 85
Section 2: Education And
Healthcare — 85
Table: Education,
2000-2005 — 85
Table: Vital Statistics,
2005-2030 — 85
Section 3: Labour Market And Spending
Power — 86
Table: Employment Indicators,
2001-2006 — 86
Table: Consumer Expenditure, 2000-2010
(US$) — 86
Table: Average Annual Manufacturing Wages,
2000-2012 (IDR) — 87
BMI
Methodology — 88
How We Generate Our Pharmaceutical
Industry Forecasts — 88
Pharmaceutical Business
Environment Ratings Methodology — 89
Ratings
Overview — 89
Table: Pharmaceutical Business Environment
Indicators — 90
Weighting — 91
Table:
Weighting Of Components — 91
Sources — 91
| 
View Cart
